Results 151 to 160 of about 24,005 (199)

Hyperactive PLCG1 induces cell-autonomous and bystander T cell activation and drug resistance. [PDF]

EMBO Rep
Zeng L, Zhang X, Xiong Y, Sato K, Hajicek N, Kogure Y, Kataoka K, Ogawa S, Sondek J, Su X.   +9 more
europepmc   +1 more source

Epigenetic profiling identifies markers of endocrine resistance and therapeutic options for metastatic castration-resistant prostate cancer. [PDF]

Cell Rep Med
Severson TM, Minnee E, Zhu Y, Schuurman K, Nguyen HM, Brown LG, Hakkola S, Menezes R, Gregoricchio S, Kim Y, Kneppers J, Linder S, Stelloo S, Lieftink C, van der Heijden MS, Nykter M, van der Noort V, Sanders J, Morris B, Jenster G, van Leenders GJ, Pomerantz M, Freedman ML, Beijersbergen RL, Urbanucci A, Wessels L, Nelson PS, Corey E, Prekovic S, Zwart W, Bergman AM.   +30 more
europepmc   +1 more source

TNG260 Is a Small-Molecule CoREST Inhibitor That Sensitizes STK11-Mutant Tumors to Anti-PD-1 Immunotherapy. [PDF]

Cancer Res
Ahronian LG, Sahu S, Zhang M, Patel AS, Geng K, Bhattacharya R, Falchook GS, Goldman JW, Spira AI, Punekar SR, Spigel DR, Wang JS, Skoulidis F, Stephens J, Meynardie M, Powell JM, Lopez A, Ranieri M, Ploszaj MA, Tan YJ, Lee YT, Yu Y, Deng J, Chen T, McCarren P, Tsai A, Hussain SS, Doyon B, Amemiya K, Ermolieff J, Shahagadkar P, Das NM, Flynn LR, Shields JA, Danielczyk L, McMillan BJ, Mignault A, Meier SR, Wu HJ, Guerin DJ, Whittington DA, Min C, Sienczylo I, Maxwell JP, DiBenedetto HJ, Watanabe H, Haines BB, Huang A, Crystal A, Andersen JN, Wu X, Wong KK.   +51 more
europepmc   +1 more source

Epigenetic Therapies in Endocrine-Related Cancers: Past Insights and Clinical Progress. [PDF]

Cancers (Basel)
Varun D, Haque M, Jackson-Oxley J, Thompson R, Kumari AA, Woodcock CL, Harris AE, Madhusudan S, Rakha E, Rutland CS, Mongan NP, Jeyapalan JN.   +11 more
europepmc   +1 more source

FSP1 and histone deacetylases suppress cancer persister cell ferroptosis. [PDF]

Sci Adv
Higuchi M, Williams AF, Stuhlfire AE, Nguyen AH, Gervasio DAG, Turkal CE, Chon S, Hangauer MJ.   +7 more
europepmc   +1 more source

Colon cancer cells evade drug action by enhancing drug metabolism. [PDF]

Oncogene
Cong B, Thakur T, Uribe AH, Stamou E, Gopinath S, Sansom O, Maddocks O, Cagan R.   +7 more
europepmc   +1 more source

Off-target binding of the histone deacetylase inhibitor vorinostat to carbonic anhydrase II and IX. [PDF]

Acta Crystallogr F Struct Biol Commun
Gulkis MC, Hodgkinson JT, Sele CP, Knecht W, McKenna R, Fisher SZ.   +5 more
europepmc   +1 more source

Efficacy of pembrolizumab and vorinostat combination in patients with recurrent and/or metastatic squamous cell carcinomas: a phase 2 basket trial. [PDF]

Nat Cancer
Borcoman E, Cabarrou B, Francisco M, Bigot F, Ghiringhelli F, Vansteene D, Legrand F, Halladjian M, Dupain C, Le Saux O, Coutzac C, Borel C, Chaltiel R, You B, Gomez-Roca C, Cousin S, Coquan E, Lambert A, Saada-Bouzid E, Durando X, Saint-Ghislain M, Frige G, Guerini-Rocco E, Tonini MM, Bièche I, Castel-Ajgal Z, Marret G, Sablin MP, Jeannot E, Andre F, Filleron T, Jimenez M, Mazzarella L, Servant N, Kamal M, Le Tourneau C.   +35 more
europepmc   +1 more source

Hybrid histone deacetylase-kinase inhibitor potentiates venetoclax-induced cell death in chronic lymphocytic leukemia. [PDF]

Hematol Transfus Cell Ther
Garnique ADMB, Carlos JAEG, Parducci NS, Tavares MT, Waitman KB, Lima K, Costa-Lotufo LV, Parise-Filho R, Machado-Neto JA.   +8 more
europepmc   +1 more source